ADMA Biologics Reports Q1 2026 Financial Results with Increased Net Income and Revenue Decline

ADMA Biologics, Inc. reported its financial results for the first quarter of 2026, revealing total revenues of $114.5 million, a slight decrease of 0.3% from $114.8 million in the same period last year. The company achieved a net income of $45.3 million, compared to $26.9 million in the prior year, marking a significant increase in profitability. The gross profit for the quarter was $80.8 million, reflecting a gross margin of 70.5%, up from 53.2% in the previous year, primarily due to a favorable product mix and the benefits of a recently approved yield enhancement manufacturing process.

In terms of operational changes, ADMA completed the sale of three plasma collection centers during the quarter, resulting in a gain of approximately $8.0 million. This divestiture is part of a strategic shift to streamline operations and enhance capital efficiency. The company now operates seven plasma collection facilities, which are crucial for sourcing the plasma needed for its products. Additionally, ADMA has expanded its product offerings, with ASCENIV sales increasing by 27.7% to $97.5 million, while BIVIGAM sales decreased by 54% to $15.4 million due to competitive pressures in the market.

The company’s balance sheet showed total assets of $665.2 million as of March 31, 2026, an increase from $624.2 million at the end of 2025. Cash and cash equivalents rose to $138.2 million, up from $87.6 million, while accounts receivable decreased to $135.9 million from $158.4 million. ADMA's total liabilities increased significantly to $274.9 million, primarily due to the addition of long-term debt associated with its credit facilities. The company has entered into a $300 million senior secured credit facility with JPMorgan, which includes a term loan and a revolving credit facility.

Looking ahead, ADMA Biologics anticipates continued growth driven by the expansion of ASCENIV's market presence and the potential for new product approvals. The company is also focused on increasing its plasma supply capabilities and enhancing its manufacturing processes. However, it faces challenges from competitive pricing tactics in the intravenous immunoglobulin (IVIG) market, which could impact future sales and profitability. The company remains committed to maintaining its operational efficiency and exploring strategic opportunities to bolster its market position.